NEW YORK ( Trefis) -- Merck (MRK) recently declared its results for the first quarter. A lot happened during this quarter that can potentially impact the company's ongoing business. During this period, it reported uniform growth across all segments with better cost control and gains from certain nonrecurring items ensured net earnings jump of nearly 67% from $1.07 billion to $1.77 billion.The noteworthy nonrecurring items were $500 million gain related to resolution of the arbitration proceedings with Johnson & Johnson (JNJ) and $134 million gain on sale of certain manufacturing assets. If we analyze the results excluding the nonrecurring items and restructuring costs, the results are still encouraging with almost 9.1% growth in earnings compared to same period last year.
Merck Worth $41 on Solid Growth, Cost Controls
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.